FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach.
Adverse effects
Efficacy
FLASH radiotherapy
FLASH workflow
Pain relief
Proton therapy
Safety
Thoracic bone metastases
Ultra-high dose rate
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
21
09
2023
accepted:
08
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
epublish
Résumé
FLASH therapy is a treatment technique in which radiation is delivered at ultra-high dose rates (≥ 40 Gy/s). The first-in-human FAST-01 clinical trial demonstrated the clinical feasibility of proton FLASH in the treatment of extremity bone metastases. The objectives of this investigation are to assess the toxicities of treatment and pain relief in study participants with painful thoracic bone metastases treated with FLASH radiotherapy, as well as workflow metrics in a clinical setting. This single-arm clinical trial is being conducted under an FDA investigational device exemption (IDE) approved for 10 patients with 1-3 painful bone metastases in the thorax, excluding bone metastases in the spine. Treatment will be 8 Gy in a single fraction administered at ≥ 40 Gy/s on a FLASH-enabled proton therapy system delivering a single transmission proton beam. Primary study endpoints are efficacy (pain relief) and safety. Patient questionnaires evaluating pain flare at the treatment site will be completed for 10 consecutive days post-RT. Pain response and adverse events (AEs) will be evaluated on the day of treatment and on day 7, day 15, months 1, 2, 3, 6, 9, and 12, and every 6 months thereafter. The outcomes for clinical workflow feasibility are the occurrence of any device issues as well as time on the treatment table. This prospective clinical trial will provide clinical data for evaluating the efficacy and safety of proton FLASH for palliation of bony metastases in the thorax. Positive findings will support the further exploration of FLASH radiation for other clinical indications including patient populations treated with curative intent. ClinicalTrials.gov NCT05524064.
Sections du résumé
BACKGROUND
BACKGROUND
FLASH therapy is a treatment technique in which radiation is delivered at ultra-high dose rates (≥ 40 Gy/s). The first-in-human FAST-01 clinical trial demonstrated the clinical feasibility of proton FLASH in the treatment of extremity bone metastases. The objectives of this investigation are to assess the toxicities of treatment and pain relief in study participants with painful thoracic bone metastases treated with FLASH radiotherapy, as well as workflow metrics in a clinical setting.
METHODS
METHODS
This single-arm clinical trial is being conducted under an FDA investigational device exemption (IDE) approved for 10 patients with 1-3 painful bone metastases in the thorax, excluding bone metastases in the spine. Treatment will be 8 Gy in a single fraction administered at ≥ 40 Gy/s on a FLASH-enabled proton therapy system delivering a single transmission proton beam. Primary study endpoints are efficacy (pain relief) and safety. Patient questionnaires evaluating pain flare at the treatment site will be completed for 10 consecutive days post-RT. Pain response and adverse events (AEs) will be evaluated on the day of treatment and on day 7, day 15, months 1, 2, 3, 6, 9, and 12, and every 6 months thereafter. The outcomes for clinical workflow feasibility are the occurrence of any device issues as well as time on the treatment table.
DISCUSSION
CONCLUSIONS
This prospective clinical trial will provide clinical data for evaluating the efficacy and safety of proton FLASH for palliation of bony metastases in the thorax. Positive findings will support the further exploration of FLASH radiation for other clinical indications including patient populations treated with curative intent.
REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05524064.
Identifiants
pubmed: 38475815
doi: 10.1186/s13014-024-02419-4
pii: 10.1186/s13014-024-02419-4
doi:
Banques de données
ClinicalTrials.gov
['NCT05524064']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Informations de copyright
© 2024. The Author(s).
Références
Fouillade C, Curras-Alonso S, Giuranno L, Quelennec E, Heinrich S, Bonnet-Boissinot S, et al. FLASH irradiation spares lung progenitor cells and limits the incidence of radio-induced senescence. Clin Cancer Res. 2020;26(6):1497–506.
doi: 10.1158/1078-0432.CCR-19-1440
pubmed: 31796518
Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. 2014;6(245):245ra93.
doi: 10.1126/scitranslmed.3008973
pubmed: 25031268
Montay-Gruel P, Petersson K, Jaccard M, Boivin G, Germond JF, Petit B, et al. Irradiation in a flash: unique sparing of memory in mice after whole brain irradiation with dose rates above 100Gy/s. Radiother Oncol. 2017;124(3):365–9.
doi: 10.1016/j.radonc.2017.05.003
pubmed: 28545957
Loo B, Schuler E, Lartey F, Rafat M, King GJ, Trovati S, et al. Delivery of Ultra-rapid Flash Radiation Therapy and demonstration of normal tissue sparing after abdominal irradiation of mice. Int J Radiat Oncol Biol Phys. 2017;98:E16.
doi: 10.1016/j.ijrobp.2017.02.101
Field SB, Bewley DK. Effects of dose-rate on the radiation response of rat skin. Int J Radiat Biol Relat Stud Phys Chem Med. 1974;26(3):259–67.
doi: 10.1080/09553007414551221
pubmed: 4547756
Vozenin MC, De Fornel P, Petersson K, Favaudon V, Jaccard M, Germond JF, et al. The advantage of FLASH Radiotherapy confirmed in mini-pig and cat-cancer patients. Clin Cancer Res. 2019;25(1):35–42.
doi: 10.1158/1078-0432.CCR-17-3375
pubmed: 29875213
Montay-Gruel P, Acharya MM, Petersson K, Alikhani L, Yakkala C, Allen BD, et al. Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species. Proc Natl Acad Sci USA. 2019;116(22):10943–51.
doi: 10.1073/pnas.1901777116
pubmed: 31097580
pmcid: 6561167
Bourhis J, Sozzi WJ, Jorge PG, Gaide O, Bailat C, Duclos F, et al. Treatment of a first patient with FLASH-radiotherapy. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2019;139:18–22.
doi: 10.1016/j.radonc.2019.06.019
Daugherty EC, Mascia A, Zhang Y, Lee E, Xiao Z, Sertorio M, et al. FLASH Radiotherapy for the treatment of symptomatic bone metastases (FAST-01): protocol for the first prospective feasibility study. JMIR Res Protoc. 2023;12:e41812.
doi: 10.2196/41812
pubmed: 36206189
pmcid: 9893728
Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA 3rd. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798–804.
doi: 10.1093/jnci/dji139
pubmed: 15928300
Mascia AE, Daugherty EC, Zhang Y, Lee E, Xiao Z, Sertorio M, et al. Proton FLASH Radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 Nonrandomized Trial. JAMA Oncol. 2023;9(1):62–9.
doi: 10.1001/jamaoncol.2022.5843
pubmed: 36273324
Foro Arnalot P, Fontanals AV, Galcerán JC, Lynd F, Latiesas XS, de Dios NR, et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 gy in 10 fractions compared with 8 gy in single fraction. Radiother Oncol. 2008;89(2):150–5.
doi: 10.1016/j.radonc.2008.05.018
pubmed: 18556080
Shuja M, Elghazaly AA, Iqbal A, Mohamed R, Marie A, Tunio MA, et al. Efficacy of 8 gy single fraction Palliative Radiation Therapy in painful bone metastases: a single Institution experience. Cureus. 2018;10(1):e2036.
pmcid: 5843385
van der Pielkenrood BJ, Bartels MMT, Kasperts N, Verhoeff JJC, et al. Pain Response after Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in patients with bone Metastases-A phase 2 Randomized Controlled Trial within a prospective cohort. Int J Radiat Oncol Biol Phys. 2021;110(2):358–67.
doi: 10.1016/j.ijrobp.2020.11.060
pubmed: 33333200
Hartsell W, Scott C, Bruner D, Scarantino C, Ivker R, Roach M, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798–804.
doi: 10.1093/jnci/dji139
pubmed: 15928300
McDonald R, Ding K, Brundage M, Meyer R, Nabid A, Chabot P, et al. Effect of Radiotherapy on painful bone metastases: a secondary analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23. JAMA Oncol. 2017;3(7):953–9.
doi: 10.1001/jamaoncol.2016.6770
pubmed: 28196208
pmcid: 5547919
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.
doi: 10.1118/1.3438081
pubmed: 20879569
Chow E, Meyer R, Ding K, Nabid A, Chabot P, Wong P, et al. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases:a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:1463–72.
doi: 10.1016/S1470-2045(15)00199-0
pubmed: 26489389
Slotman D, Bartels M, Ferrer C, Bos C, Bartels L, Boomsma M et al. Focused Ultrasound and RadioTHERapy for non-invasive palliative pain treatment in patients with bone metastasis: a study protocol for the three-armed randomized controlled FURTHER trial. 2022; https://doi.org/10.1186/s13063-022-06942-1 .